Most people who ask how to get prescribed Ozempic for weight loss already meet the definition the weight-management labels use. The harder parts come after that: asking for the right product by name, choosing where to ask, and deciding how it gets paid for. Each of those has its own article on this site, starting with what an online intake actually asks. This page puts them in order.
Who the weight-management labels cover
Two injectable products are approved for chronic weight management in adults. Wegovy injection is indicated, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain the reduction long term in adults with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition. It also carries a cardiovascular risk-reduction indication in adults with established cardiovascular disease and obesity or overweight.[1] Zepbound uses the same weight-management wording and adds moderate to severe obstructive sleep apnea in adults with obesity.[2]
The indication text itself contains no number. The familiar cut-points come from how the pivotal trials defined those words. A 68-week Wegovy trial summarized on its label enrolled 1,961 patients with a BMI of 30 or greater, or 27 to 29.9 with at least one weight-related condition such as dyslipidemia or hypertension.[1] Zepbound’s first trial used the same structure across 2,539 adults, naming dyslipidemia, hypertension, obstructive sleep apnea and cardiovascular disease as qualifying conditions.[2] A BMI of 30, or 27 plus one of those diagnoses, is therefore the working threshold a prescriber will use.
Why asking for Ozempic means asking for a diabetes drug
Ozempic is the same molecule as Wegovy, but its label lists only type 2 diabetes uses: glycemic control, cardiovascular risk reduction in patients with established disease, and kidney outcomes in patients with chronic kidney disease.[3] Mounjaro stands in the same relation to Zepbound, labeled for glycemic control and cardiovascular risk reduction in type 2 diabetes.[4] The dose ceilings and trial populations differ too, which the Wegovy and Ozempic comparison sets out.
Writing Ozempic for someone without diabetes is off-label prescribing: a licensed prescriber may do it, but the use is outside what the FDA reviewed for that product. It has been common. In a 20% sample of Medicare Part D, 9.0% of 126,263 new semaglutide or tirzepatide users between 2019 and 2023 had no evidence of diabetes, rising to 13.8% in 2023.[5] In Denmark’s national registries, the share of new Ozempic users with a record of type 2 diabetes fell from 99% in 2018 to 67% in 2022, then recovered to 87% in 2023.[6]
The practical problem with an off-label request is money rather than legality. Insurance criteria are written against an indication, and Lilly’s self-pay card for Zepbound requires a prescription “for an approved use consistent with FDA approved product labeling.”[7] For weight loss without diabetes, the request that lines up with both is Wegovy or Zepbound by name.
Qualifying is common; being prescribed is not
The strongest evidence on access says the gap sits between eligibility and the prescription pad. A cross-sectional study of the Mass General Brigham system from 2018 to 2022 identified 2,469,474 adults and found 1,110,251 of them, 45.0%, eligible for anti-obesity medication under the BMI 30, or 27-plus-condition, definition. Of those eligible, 1.4% had a prescription. Commercial insurance, female sex, younger age, higher BMI and more weight-related conditions were each associated with higher prescribing.[9]
A Yale staff-model HMO using a comparable eligibility definition reached a very different number. Among 6,225 eligible adults, 18.3% had been prescribed a GLP-1 or dual agonist for obesity. The disparities reported in national data did not appear: Black patients had an adjusted odds ratio of 0.94 (95% CI, 0.78 to 1.13), and patients in the most deprived quintile 0.87 (0.65 to 1.16), neither statistically different from the comparison groups.[10]
Those two figures are not directly comparable. The years, the products available and the populations differ, and the first study was co-authored by employees of a manufacturer. But they point the same way. The rate at which eligible people leave with a prescription depends more on the system they ask, and how it is paid, than on their own chart.
Route one: the doctor who already has your chart
A primary-care physician starts with the most information: medication list, history, prior labs and any diagnosis that turns overweight into a qualifying condition. That makes this route the strongest on screening and, for an insured patient, usually the one that can start a coverage request. The weakness is the one the Mass General Brigham figure describes. Prescribing rates vary widely between practices, and some clinicians do not prescribe these drugs for weight at all.
Coming prepared shortens the visit: a recent weight and height, diagnoses such as hypertension, sleep apnea or prediabetes, a list of current medications, and the name of the product being requested. If the answer is no, asking for a referral is a reasonable next step.
Route two: an obesity medicine clinic
Hospital-based weight-management programs and clinicians certified in obesity medicine treat this as their main work. They typically run a fuller workup, including bloodwork, and are more likely to manage dose escalation, side effects and the plan for stopping. The trade-off is access: many require a referral, waits can be long, and the program fee is separate from the drug. A primary-care weight program in Michigan illustrates the limits of adding capacity. It referred more patients to surgery and diet programs and produced 4.4% greater weight loss than matched controls, yet showed no difference in anti-obesity medication prescribing.[11]
Route three: telehealth
A telehealth service replaces the visit with an online intake and a clinician review, sometimes with a video call. It is the fastest route and the one most readers of this site are weighing. The prescriber must be licensed in the state where the patient is located, which is why service areas differ; the rules are covered in the state telehealth article. The cost structure, including the bloodwork neither route prices, is compared in the telehealth and in-person cost comparison. Patterns that deserve a second look before paying are in the red-flags article.
What every route has to screen for
Whichever door is used, the same labels govern. Wegovy, Zepbound, Ozempic and Mounjaro all carry a boxed warning on thyroid C-cell tumors and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.[1][2][3][4] A prescriber who never asks about that history has skipped the one question every label puts first. The full contraindication list, and the conditions that are conversations rather than rules, are in the article on who should not take these drugs.
Paying for it: coverage or cash
With insurance, the prescription is the start of a second process. Most plans that cover a weight-management product require prior authorization, which is described in the prior authorization article. How plan design, Medicare and coverage withdrawals shape the choice is in the insurance and cash-pay comparison.
Without coverage, both manufacturers sell direct. NovoCare Pharmacy lists Wegovy pens at $349 a month for doses from 0.25 mg to 2.4 mg and $399 for the 7.2 mg dose, with patients new to the offer paying $199 for each of their first two months through December 31, 2026. Wegovy tablets are listed at $149 a month for 1.5 mg, $199 for 4 mg, and $299 for 9 mg and 25 mg. A valid prescription is required.[8]
Lilly lists the Zepbound KwikPen at $299 for 2.5 mg and $399 for 5 mg. The 7.5 mg to 15 mg doses are $449 when each refill is bought within 45 days of the last delivery; otherwise the listed regular prices are $499 for 7.5 mg and $699 for 10 mg, 12.5 mg and 15 mg. A month is defined as 28 days, and the card ends December 31, 2026.[7] Card conditions and the insured-patient offers are detailed in the savings-card article.
The compounded route
Much of the telehealth market sells compounded semaglutide or tirzepatide instead of a branded pen. Compounded drugs are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality before they are marketed.[12] A compounded preparation also falls outside insurance coverage and outside both manufacturer programs above. How it differs from the approved products is in the compounded and brand comparison, and current cash prices are on the compounded semaglutide board.
What this page cannot settle
Eligibility under a label is a starting condition, not a decision. It does not establish that a drug is right for a particular person, and it says nothing about whether a given plan will pay. Those answers come from a prescriber who has the history and from the plan’s own documents. What this site records about individual services is in the seller write-ups.